Cholestatic Pruritus Market Expected to Experience Major Growth by 2032, According to DelveInsight | Escient Pharma, GlaxoSmithKline, Mirum Pharma, Albireo, Regeneron Pharma

DelveInsight's "Cholestatic Pruritus Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Cholestatic Pruritus, historical and forecasted epidemiology as well as the Cholestatic Pruritus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Cholestatic Pruritus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cholestatic Pruritus Market Forecast
https://www.delveinsight.com/sample-request/cholestatic-pruritus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Cholestatic Pruritus Market Report:
• The Cholestatic Pruritus market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In January 2025, Mirum Pharmaceuticals is actively enrolling participants in a Phase 3 clinical trial evaluating maralixibat for treatment-resistant pruritus associated with rare cholestatic conditions. Known as the EXPAND trial (NCT06553768), it aims to recruit up to 90 individuals aged six months and older across multiple sites in the U.S., South America, Europe, and the Middle East. Recruitment is currently underway at locations in Los Angeles, New Orleans, and New York, with enrollment expected to conclude in 2026, as detailed in a recent Mirum press release outlining financial and corporate updates.
• In November 2024, Ipsen (Euronext: IPN; ADR: IPSEY) presented data at the American Association for the Study of Liver Diseases (AASLD) evaluating the long-term efficacy and safety of Bylvay® in patients from two Phase III open-label extension studies. The late-breaking abstract (#5045) focused on the PEDFIC 2 study in Progressive Familial Intrahepatic Cholestasis (PFIC), while the oral presentation ASSERT-EXT (#50) examined its effects in Alagille syndrome (ALGS). Findings revealed sustained efficacy, along with improvements in height, weight, and sleep, for patients treated with Bylvay for at least 72 weeks in both rare cholestatic conditions.
• In November 2024, GSK reported positive topline results from its ongoing global Phase III GLISTEN trial, which is assessing linerixibat for treating cholestatic pruritus (persistent itching) in adults. Cholestatic pruritus is a frequent symptom of primary biliary cholangitis (PBC), a rare autoimmune liver disease. The study aims to evaluate the safety and effectiveness of linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor, in managing pruritus in PBC patients.
• According to research conducted by Yoshikawa et al. in 2021, pruritus prevalence is documented at 70% among individuals with primary biliary cholangitis (PBC). Additionally, pruritus has been observed in 8% of patients with chronic hepatitis B and in approximately 2.5-20% of those with chronic hepatitis C.
• Pruritus is commonly linked to cholestatic liver conditions such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Review articles suggest an occurrence of pruritus in approximately 20-70% of individuals with PBC and in 38% of those affected by PSC.
• Key Cholestatic Pruritus Companies: Escient Pharmaceuticals, GlaxoSmithKline, Mirum Pharmaceuticals, Albireo, Regeneron Pharmaceuticals, Avior Bio, and others
• Key Cholestatic Pruritus Therapies: EP547, Linerixibat, LUM001, A4250, Dupilumab, AV104, and others
• The Cholestatic Pruritus market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cholestatic Pruritus pipeline products will significantly revolutionize the Cholestatic Pruritus market dynamics.

Cholestatic Pruritus Overview
Cholestatic pruritus, also known as cholestatic itch, is a distressing symptom characterized by intense itching that occurs in individuals with cholestatic liver diseases. Cholestatic liver diseases are conditions where the flow of bile from the liver to the small intestine is impaired, leading to the accumulation of bile acids and other substances in the bloodstream.

Get a Free sample for the Cholestatic Pruritus Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/cholestatic-pruritus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cholestatic Pruritus Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cholestatic Pruritus Epidemiology Segmentation:
The Cholestatic Pruritus market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Cholestatic Pruritus
• Prevalent Cases of Cholestatic Pruritus by severity
• Gender-specific Prevalence of Cholestatic Pruritus
• Diagnosed Cases of Episodic and Chronic Cholestatic Pruritus

Download the report to understand which factors are driving Cholestatic Pruritus epidemiology trends @ Cholestatic Pruritus Epidemiology Forecast
https://www.delveinsight.com/sample-request/cholestatic-pruritus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cholestatic Pruritus Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cholestatic Pruritus market or expected to get launched during the study period. The analysis covers Cholestatic Pruritus market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cholestatic Pruritus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cholestatic Pruritus Therapies and Key Companies
• EP547: Escient Pharmaceuticals
• Linerixibat: GlaxoSmithKline
• LUM001: Mirum Pharmaceuticals
• A4250: Albireo
• Dupilumab: Regeneron Pharmaceuticals
• AV104: Avior Bio

Discover more about therapies set to grab major Cholestatic Pruritus market share @ Cholestatic Pruritus Treatment Landscape
https://www.delveinsight.com/sample-request/cholestatic-pruritus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cholestatic Pruritus Market Strengths
• Increasing prevalence of Cholestatic Pruritus in the 7MM
• Complex underlying mechanisms have been identified and various therapeutic options developed.

Cholestatic Pruritus Market Opportunities
• Current treatments for cholestatic pruritus are inadequate, and additional, more effective therapeutic options are required.

Scope of the Cholestatic Pruritus Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Cholestatic Pruritus Companies: , and others
• Key Cholestatic Pruritus Therapies: EP547, Linerixibat, LUM001, A4250, Dupilumab, AV104, and others
• Cholestatic Pruritus Therapeutic Assessment: Cholestatic Pruritus current marketed and Cholestatic Pruritus emerging therapies
• Cholestatic Pruritus Market Dynamics: Cholestatic Pruritus market drivers and Cholestatic Pruritus market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Cholestatic Pruritus Unmet Needs, KOL's views, Analyst's views, Cholestatic Pruritus Market Access and Reimbursement

To know more about Cholestatic Pruritus companies working in the treatment market, visit @ Cholestatic Pruritus Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/cholestatic-pruritus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Cholestatic Pruritus Market Report Introduction
2. Executive Summary for Cholestatic Pruritus
3. SWOT analysis of Cholestatic Pruritus
4. Cholestatic Pruritus Patient Share (%) Overview at a Glance
5. Cholestatic Pruritus Market Overview at a Glance
6. Cholestatic Pruritus Disease Background and Overview
7. Cholestatic Pruritus Epidemiology and Patient Population
8. Country-Specific Patient Population of Cholestatic Pruritus
9. Cholestatic Pruritus Current Treatment and Medical Practices
10. Cholestatic Pruritus Unmet Needs
11. Cholestatic Pruritus Emerging Therapies
12. Cholestatic Pruritus Market Outlook
13. Country-Wise Cholestatic Pruritus Market Analysis (2019-2032)
14. Cholestatic Pruritus Market Access and Reimbursement of Therapies
15. Cholestatic Pruritus Market Drivers
16. Cholestatic Pruritus Market Barriers
17. Cholestatic Pruritus Appendix
18. Cholestatic Pruritus Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Cholestatic Pruritus Pipeline https://www.delveinsight.com/report-store/cholestatic-pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Cholestatic Pruritus Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cholestatic Pruritus market. A detailed picture of the Cholestatic Pruritus pipeline landscape is provided, which includes the disease overview and Cholestatic Pruritus treatment guidelines.

Cholestatic Pruritus Epidemiology https://www.delveinsight.com/report-store/cholestatic-pruritus-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Cholestatic Pruritus Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholestatic Pruritus epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Parp Poly Adp-ribose Polymerase Inhibitor Market: https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight
• Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market
• Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market
• Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.